Larimar Therapeutics/$LRMR
1D1W1MYTD1Y5YMAX
Capital at risk
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
- Ticker
- $LRMR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 71
- Headquarters
- Bala Cynwyd, United States
- Website
- www.larimartx.com
LRMR Metrics
BasicAdvanced
$400M
-
-$1.93
0.75
-
Price and volume
Market cap
$400M
Beta
0.75
52-week high
$6.42
52-week low
$2.72
Average daily volume
1.1M
Financial strength
Current ratio
4.703
Quick ratio
4.582
Long term debt to equity
2.947
Total debt to equity
3.891
Profitability
EBITDA (TTM)
-178.685
Management effectiveness
Return on assets (TTM)
-70.96%
Return on equity (TTM)
-139.63%
Valuation
Price to book
3.14
Price to tangible book (TTM)
3.14
Price to free cash flow (TTM)
-2.199
Free cash flow yield (TTM)
-45.47%
Free cash flow per share (TTM)
-1.741
Growth
Earnings per share change (TTM)
23.35%
3-year earnings per share growth (CAGR)
31.50%
What the Analysts think about LRMR
Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.
Analyst projections of the future price of Larimar Therapeutics stock.
Bulls say / Bears say
FDA Breakthrough Therapy Designation underscores potential for nomlabofusp to demonstrate substantial improvement over existing Friedreich’s ataxia treatments, expediting development and review timelines (Reuters)
Initiation of rolling BLA submission with the first module submitted in June 2026 and FDA alignment on using skin frataxin as a novel surrogate endpoint sets the stage for submission completion in H2 2026 and potential accelerated approval path (Thomson Reuters)
Strong fiscal position with $156.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026 provides runway into Q3 2027, supporting ongoing development and Phase 3 initiation (Thomson Reuters)
Safety concerns arise from anaphylaxis events in the open label study, with 10 of 43 patients experiencing the reaction, potentially complicating regulatory review and patient acceptance (Reuters)
High cash burn rate reflected by a net loss of $29.6 million in Q1 2026 indicates potential need for further capital raises ahead of commercialization, risking dilution (Reuters)
Recent equity offering triggered a 10.8% share price drop in extended trading, highlighting dilution risk and investor sensitivity to funding-dependent clinical-stage biotechs (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
LRMR Financial Performance
Revenues and expenses
LRMR Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing LRMR
AllUSDGBPEUR
Fund name | Fund size | $LRMR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.